Aripiprazole LA-Zuclopenthixol MA
From Psychiatrienet
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
Switch medication from Aripiprazole LA to Zuclopenthixol MA.[1] [2]
Stop Aripiprazole LA - Stop or reduce drug, depending on symptomatology and (expected) adverse reactions.
- The effects of both drugs will be superimposed for several days.
Start Zuclopenthixol MA- Day 1: Start drug according general dosing advice.
More information- During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
- There is a possibility of QT interval prolongation.[3]
- Zuclopenthixol_MA = Zuclopenthixol acetate [4]
- More information you'll find in the summary of product characteristics (SPC) of aripiprazole depot injection. [5]
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
- ↑ SPC Zuclopenthixol acetate
- ↑ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002755/WC500156111.pdf SPC of the European Medicines Agency on aripiprazole depot
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
